Related Experiment Video
Updated: Jul 9, 2025
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
Botulinum toxin treatment in parkinsonism
Charenya Anandan1, Joseph Jankovic2
1Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, United States of America; Neurology Care Line, Michael E DeBakey VA Medical Center, Houston, TX, United States of America.
Journal of the Neurological Sciences
|December 6, 2023
Summary
Botulinum toxin (BoNT) offers therapeutic benefits beyond its initial FDA approvals for movement disorders. Expert experience suggests BoNT is beneficial for various conditions associated with parkinsonism, even without specific FDA approval.
Area of Science:
- Neurology
- Pharmacology
- Gastroenterology
Background:
- Botulinum toxin (BoNT) received FDA approval in 1989 for specific neurological and ophthalmological conditions.
- Its therapeutic applications have significantly expanded beyond the initial approved indications.
- This review focuses on the evolving use of BoNT in managing symptoms related to parkinsonism.
Purpose of the Study:
- To provide a narrative review of the therapeutic applications of Botulinum toxin (BoNT).
- To explore the efficacy of BoNT in treating tremors, dystonia, sialorrhea, and bladder dysfunction.
- To examine the role of BoNT in managing levodopa-induced dyskinesia and other parkinsonism-related issues.
Main Methods:
- A narrative review of existing literature and expert clinical experience.
- Analysis of therapeutic outcomes for various conditions treated with Botulinum toxin.
- Focus on indications beyond FDA-approved uses.
Main Results:
- Botulinum toxin (BoNT) demonstrates therapeutic benefits in managing tremors and dystonia.
- Effective in treating sialorrhea (excessive salivation) and bladder autonomic symptoms.
- Shows promise in alleviating levodopa-induced dyskinesia in parkinsonism patients.
Conclusions:
- Botulinum toxin (BoNT) is a valuable therapeutic option for a range of symptoms in parkinsonism.
- Expert clinical experience supports its use for several off-label indications.
- Further research and potential FDA approvals may expand its role in neurological disorders.
Related Concept Videos
01:24Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
684
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
684
01:15Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557
01:31Skeletal Muscle Relaxants: Therapeutic Uses
488
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
488
01:28Classification of Skeletal Muscle Relaxants
2.5K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.5K
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195